What is SaNOtize Research & Development?
SaNOtize Research & Development is a global pharmaceutical entity focused on harnessing the antimicrobial properties of nitric oxide (NO). Their proprietary technology has led to the development of innovative products, including a nasal spray designed to offer protection against viruses. The company is actively engaged in educating healthcare providers, potential business partners, and investors about their cutting-edge technology and ongoing clinical development programs, positioning itself as a leader in advanced medical solutions.
How much funding has SaNOtize Research & Development raised?
SaNOtize Research & Development has raised a total of $26.5M across 2 funding rounds:
Series A
$2.5M
Series B
$24M
Series A (2020): $2.5M with participation from OurCrowd
Series B (2022): $24M led by ABC International, OurCrowd, and Horizons Ventures
Key Investors in SaNOtize Research & Development
ABC International
ABC International is an undisclosed investor participating in the funding round, indicating a strategic interest in SaNOtize's innovative pharmaceutical technology.
OurCrowd
OurCrowd is a prominent investment platform that facilitates investments in startups and early-stage companies, suggesting a focus on high-growth potential ventures like SaNOtize.
Horizons Ventures
Horizons Ventures specializes in deep science and technology investments aimed at advancing humanity, aligning with SaNOtize's mission to develop groundbreaking medical solutions.
What's next for SaNOtize Research & Development?
With a substantial injection of capital, SaNOtize Research & Development is poised for accelerated growth and market expansion. The recent major strategic investment signals strong confidence from backers in the company's potential to disrupt the healthcare sector with its nitric oxide-based antiviral technology. Future endeavors will likely focus on scaling production, broadening clinical trials, and securing regulatory approvals to bring their protective nasal spray and other NO-based therapeutics to a wider global audience. This financing will be instrumental in solidifying SaNOtize's position as a key player in the fight against viral infections.
See full SaNOtize Research & Development company page
